Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Novel therapeutic approaches in chronic myeloid leukemia
NÖ Yurttaş, AE Eşkazan - Leukemia Research, 2020 - Elsevier
The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation
H Mu, X Zhu, H Jia, L Zhou, H Liu - Frontiers in Oncology, 2021 - frontiersin.org
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha
YD Irani, A Hughes, CH Kok, J Clarson… - British Journal of …, 2023 - Wiley Online Library
The addition of interferon to tyrosine kinase inhibitors (TKIs), to improve deep molecular
response (DMR) and potentially treatment‐free remission (TFR) rates in chronic‐phase …
response (DMR) and potentially treatment‐free remission (TFR) rates in chronic‐phase …
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for …
F Guilhot, F Rigal-Huguet, J Guilhot, AP Guerci-Bresler… - Leukemia, 2021 - nature.com
The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing
imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg+ cytarabine (AraC), and IM 400 mg+ …
imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg+ cytarabine (AraC), and IM 400 mg+ …
[HTML][HTML] Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors
J Shaya, K Pettit, M Kandarpa, D Bixby, J Mercer… - … Myeloma and Leukemia, 2022 - Elsevier
Background The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically
improved outcomes for patients with chronic myeloid leukemia (CML); however, the …
improved outcomes for patients with chronic myeloid leukemia (CML); however, the …
Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors
K Jun, Q Ya-Zhen, Z Xiao-Su… - Therapeutic …, 2021 - journals.sagepub.com
Background: Currently, the goal of chronic myeloid leukemia (CML) treatment is normal
survival and good quality of life without life-long treatment, namely,“treatment-free …
survival and good quality of life without life-long treatment, namely,“treatment-free …
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
D Rea - Blood Advances, 2020 - ashpublications.org
The paradigm for managing patients with chronic myeloid leukemia is evolving. In the recent
past, restoring a normal life expectancy while patients are receiving never-ending targeted …
past, restoring a normal life expectancy while patients are receiving never-ending targeted …
Eradicating residual chronic myeloid leukaemia: basic research lost in translation
H Zhao, M Deininger - The Lancet Haematology, 2021 - thelancet.com
Chronic myeloid leukaemia is the poster child for reducing scientific progress to clinical
practice. A series of fundamental discoveries, each building on the foundation of previous …
practice. A series of fundamental discoveries, each building on the foundation of previous …
Analisis skor hasford sebagai prediktor respons molekuler mayor pada penderita chronic myeloid leukemia yang mendapat terapi nilotinib
M Riswan, I Irwandi, M Fuad… - Jurnal Kedokteran Syiah …, 2023 - jurnal.usk.ac.id
Pendahuluan: Chronic myeloid leukemia (CML) merupakan neoplasma myeloproliferative
clonal ditandai dengan ekspansi sel punca sumsum tulang pluripoten yang tidak terkendali …
clonal ditandai dengan ekspansi sel punca sumsum tulang pluripoten yang tidak terkendali …